Apellis Pharmaceuticals, Inc. (Nasdaq:APLS) is excited to announce the pricing of its public offering of 3,174,603 shares of common stock and pre-funded warrants to purchase 2,380,956 shares of its common stock. With a public offering price of $63.00 per share and $62.9999 per pre-funded warrant, the offering is expected to generate approximately $350 million in gross proceeds before deducting underwriting discounts and commissions and offering expenses. As an added incentive, the underwriters have been granted a 30-day option to purchase up to 833,333 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions. All of the shares and pre-funded warrants in the offering are being sold by Apellis, and the offering is expected to close on February 27, 2023, subject to customary closing conditions.
J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, and Evercore Group L.L.C. are teaming up to act as joint book-running managers for the upcoming offering. Additionally, Robert W. Baird & Co. Incorporated and Raymond James & Associates, Inc. are joining the effort as co-managers. Get ready for an exciting offering!
Apellis Pharmaceuticals, Inc. is a pioneering biopharmaceutical company that is devoted to discovering and developing life-changing therapies for some of the most complex diseases. We have made tremendous progress since introducing the first new class of complement medicine in 15 years, with two approved medicines targeting C3, including the only therapy for geographic atrophy, a major cause of blindness. We are confident that there is still much more to discover in our endeavor to unlock the potential of C3 for the betterment of many serious diseases, with close to a dozen clinical and pre-clinical programs underway.